These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 11709318)

  • 1. Staphylococcus aureus mutants isolated via exposure to nonfluorinated quinolones: detection of known and unique mutations.
    Roychoudhury S; Twinem TL; Makin KM; Nienaber MA; Li C; Morris TW; Ledoussal B; Catrenich CE
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3422-6. PubMed ID: 11709318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
    Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones.
    Griggs DJ; Marona H; Piddock LJ
    J Antimicrob Chemother; 2003 Jun; 51(6):1403-7. PubMed ID: 12716775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
    Yagüe Guirao G; Martínez-Toldos MC; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez-Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
    Rev Esp Quimioter; 2000 Sep; 13(3):271-5. PubMed ID: 11086276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.
    Linde HJ; Schmidt M; Fuchs E; Reischl U; Niller HH; Lehn N
    Antimicrob Agents Chemother; 2001 May; 45(5):1553-7. PubMed ID: 11302827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus.
    Yoon EJ; Lee CY; Shim MJ; Min YH; Kwon AR; Lee J; Choi EC
    Chemotherapy; 2010; 56(2):153-7. PubMed ID: 20407243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
    Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains.
    Wang T; Tanaka M; Sato K
    Antimicrob Agents Chemother; 1998 Feb; 42(2):236-40. PubMed ID: 9527766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.
    Ince D; Hooper DC
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2755-64. PubMed ID: 11557465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
    Takei M; Fukuda H; Kishii R; Hosaka M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3544-7. PubMed ID: 11709337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
    Ng EY; Trucksis M; Hooper DC
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
    Yun HJ; Min YH; Jo YW; Shim MJ; Choi EC
    Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
    Fukuda H; Hori S; Hiramatsu K
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.
    Takahata M; Yonezawa M; Kurose S; Futakuchi N; Matsubara N; Watanabe Y; Narita H
    J Antimicrob Chemother; 1996 Sep; 38(3):543-6. PubMed ID: 8889728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staphylococcus aureus mutants selected by BMS-284756.
    Discotto LF; Lawrence LE; Denbleyker KL; Barrett JF
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3273-5. PubMed ID: 11600399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular diversity of quinolone resistance in genetically related clinical isolates of Staphylococcus aureus and susceptibility to newer quinolones.
    Guirao GY; Martínez Toldos MC; Mora Peris B; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
    J Antimicrob Chemother; 2001 Feb; 47(2):157-61. PubMed ID: 11157899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
    Fournier B; Hooper DC
    Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.